Proteome Sciences PLC Launch of Single Cell Proteomics Services (2669O)

TIDMPRM

RNS Number : 2669O

Proteome Sciences PLC

02 October 2023

2 October 2023

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Launch of Commercial Single Cell Proteomics Services

 
 
   Proteome Sciences plc is pleased to announce the launch of SysQuant(R) 
   SCP, the commercial service for single cell proteomics using the 
   power of its TMTpro(TM) isobaric labelling reagents. Where more 
   traditional approaches can measure a few 10s of proteins on each 
   cell using antibody labelling, SysQuant(R) SCP can identify more 
   than 1,000 proteins in each study of 576 single cells and provides 
   novel insights into individual cell biology and heterogeneity. 
   Proteome Sciences is one of the first commercial providers of such 
   studies which are expected to significantly improve the performance 
   of drug development across multiple diseases including cancer, 
   neurodegeneration, respiratory and cardiac health, and metabolic 
   disorders. Whilst in its infancy, the field of single cell proteomics 
   is expected to grow rapidly as drug developers look to integrate 
   single cell genomic data with knowledge of protein changes. At 
   the same time, the complexity of the process along with the need 
   to purchase and maintain costly equipment represents a significant 
   barrier to entry. 
 
   The SysQuant(R) SCP pipeline generates and analyses quantitative 
   mass spectrometry data to reveal subtle changes not only in individual 
   cells but also within sub-populations of that same main cell type. 
   This data will greatly improve understanding of the biological 
   drivers of heterogeneity and evolution in the contexts of disease 
   and response to therapy, which will offer new therapeutic and diagnostic 
   targets for personalized medicine. 
 
   Commenting on the launch of SysQuant(R) SCP, Dr. Ian Pike Chief 
   Scientific Officer stated: 
   "This is an important step for Proteome Sciences as we have adapted 
   cutting-edge techniques developed in academia to make them available 
   to the pharmaceutical and biotechnology industries through SysQuant(R) 
   SCP. We have built a robust platform that will provide customers 
   with transformational data enabling a deeper understanding of disease 
   biology and how drugs are interacting with their targets. SysQuant(R) 
   SCP studies are highly complementary to our established workflows 
   performed on larger samples and open up a new customer base needing 
   access to this valuable novel single cell information." 
 
   Dr. Mariola Soehngen, Chief Executive Officer commented: 
   "We are pleased to be one of the first CROs providing single cell 
   proteomics to our customers. The launch of SysQuant(R) SCP is part 
   of our growth strategy along with the opening of a US facility 
   in San Diego. We believe that broadening our range of services 
   and increasing capacity are essential as the wider pharmaceutical 
   industry increasingly recognises the need to study changes in protein 
   expression and function to further advance and accelerate the drug 
   development process." 
 
 
 
 
 
   Proteome Sciences plc 
 Dr. Mariola Soehngen, Chief Executive Officer     Tel: [phone] 
  Dr. Ian Pike, Chief Scientific Officer 
 Richard Dennis, Chief Commercial Officer 
  Abdelghani Omari, Chief Financial Officer 
 
 Allenby Capital Limited (Nominated Adviser & Broker) 
 John Depasquale / Jeremy Porter (Corporate        Tel: [phone] 
  Finance) 
  Stefano Aquilino / Tony Quirke (Equity 
  Sales & Corporate Broking) 
 
 

About Proteome Sciences plc. ( www.proteomics.com )

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant(R) and TMT(R)MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator(TM) provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUPGCPUUPWPUG

(END) Dow Jones Newswires

October 02, 2023 02:00 ET (06:00 GMT)